Apo-Valgan

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg

Disponible desde:

Apotex NZ Ltd

Designación común internacional (DCI):

Valganciclovir hydrochloride 496.3 mg (= valganciclovir 450 mg)

Dosis:

450 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Valganciclovir hydrochloride 496.3mg equivalent to valganciclovir 450 mg Excipient: Crospovidone Microcrystalline cellulose Opadry pink 80W540006 Purified water Stearic acid

Unidades en paquete:

Blister pack, Al/Al, 60 tablets

clase:

Prescription

tipo de receta:

Prescription

Fabricado por:

Apotex Pharmachem India Pvt. Ltd.

indicaciones terapéuticas:

Apo-Valgan is indicated for the treatment of cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS) patients.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Al/Al - 60 tablets - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Bottle, HDPE - 60 tablets - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Bottle, HDPE - 120 tablets - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Bottle, HDPE - 180 tablets - 24 months from date of manufacture stored at or below 25°C protect from light and moisture

Fecha de autorización:

2012-07-05